Across the recent three months, 5 analysts have shared their insights on Y-mAbs Therapeutics (NASDAQ:YMAB), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $21.0, a high estimate of $23.00, and a low estimate of $17.00. Experiencing a 3.09% decline, the current average is now lower than the previous average price target of $21.67.
Investigating Analyst Ratings: An Elaborate Study
The standing of Y-mAbs Therapeutics...
ログインすると全部閲覧できます。
ログイン
